You are here

Nerve Ablation Device Gets 501(k) Clearance for Chronic Pain

Minimally Invasive Procedure Uses Radio Waves to Thwart Pain

Medtronic has received FDA clearance for its Accurian radio-frequency ablation system for nerve tissues; the device is designed to treat chronic pain via a minimally invasive procedure.

A current produced by radio waves heats up small patches of nerves to stop them from sending pain signals. The system also uses advanced software that controls the amount of power delivered and the temperature of the procedure, ensuring more consistent and predictable lesion formations.

Medtronic says that its Accurian platform can perform standard, pulsed, and enhanced ablation procedures, using internally cooled radio frequency probes to create various lesion shapes, sizes, and volumes. It has independent channel control and chip-enhanced probes for easy on-screen identification, and smart features, such as downloadable procedure reports.

Chronic pain is a disabling condition that affects approximately 100 million American adults. The annual treatment cost of chronic pain and related lost productivity is estimated to be $635 billion.

Source: FierceBiotech, February 27, 2019; Medtronic, February 27, 2019

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
More Than 32% of Patients Responded in Trial
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria